Magdalena Sakowicz, B. Jagielska, L. Bodnar, Janusz Jaroszyński, Maciej Krzakowski
{"title":"Implementation of the Polish version of the 11th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-11): importance for oncology","authors":"Magdalena Sakowicz, B. Jagielska, L. Bodnar, Janusz Jaroszyński, Maciej Krzakowski","doi":"10.5603/ocp.2023.0032","DOIUrl":"https://doi.org/10.5603/ocp.2023.0032","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"12 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81570260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sajad Hamidi, N. Seyedfatemi, M. Mardani-Hamooleh, Z. Abbasi, H. Hamidi
{"title":"The effect of spirituality-based education on the meaning of life in cancer patients: a quasi-experimental study","authors":"Sajad Hamidi, N. Seyedfatemi, M. Mardani-Hamooleh, Z. Abbasi, H. Hamidi","doi":"10.5603/ocp.2023.0034","DOIUrl":"https://doi.org/10.5603/ocp.2023.0034","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"52 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80714428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jakub Pytlos, J. Pałucki, M. Lenarcik, Ireneusz Pierzankowski, A. Klimczak, T. Olesiński
In this case series we present the cases of two patients at a metastatic stage of stomach gastrointestinal stromal tumor, who received treatment with imatinib. After a period of disease stability patients showed signs of resistance to the first-line therapy and despite the promising switch to sunitinib, developed life-threatening complications. Salvage surgeries were performed, aimed at preserving patients life and simultaneously reducing the tumor mass. Operation greatly improved patients condition and allowed for successful continuation of tyrosine kinase inhibitor treatment, showing that surgery should be considered a viable complement to the chemotherapeutical treatment.
{"title":"Individualized surgical treatment in patients with advanced gastrointestinal stromal tumor — a case series","authors":"Jakub Pytlos, J. Pałucki, M. Lenarcik, Ireneusz Pierzankowski, A. Klimczak, T. Olesiński","doi":"10.5603/ocp.2023.0023","DOIUrl":"https://doi.org/10.5603/ocp.2023.0023","url":null,"abstract":"In this case series we present the cases of two patients at a metastatic stage of stomach gastrointestinal stromal tumor, who received treatment with imatinib. After a period of disease stability patients showed signs of resistance to the first-line therapy and despite the promising switch to sunitinib, developed life-threatening complications. Salvage surgeries were performed, aimed at preserving patients life and simultaneously reducing the tumor mass. Operation greatly improved patients condition and allowed for successful continuation of tyrosine kinase inhibitor treatment, showing that surgery should be considered a viable complement to the chemotherapeutical treatment.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"19 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80452785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Kocańda, Michał Chrobot, M. Samardakiewicz, M. Jabłoński
Introduction. The profession of psycho-oncologist in Poland is not sufficiently regulated by law. Current solutions in the system involve contradictory regulations on obtaining qualifications to practice, which produces in effect systemic chaos and result in limited availability of services provided to oncology patients and their families by practitioners of this demanding profession. Material and methods. A survey conducted among psycho-oncologists concerning their professional identity was used in order to examine their opinion on the current legal regulations of this profession and the possible consequences of incoherent law solutions. The study used an original anonymous questionnaire entitled Survey on selected aspects of the psycho-oncology profession in the context of its scope and method of legal regulation and the Job Satisfaction Scale questionnaire. Results. The study showed that the inconsistency in legal regulations may result in restricted access to this profession, indicated doubts concerning the legal credentials required to use the professional title of psycho-oncologist and the lack of symmetry in individual competencies of practitioners with different underlying profession. Conclusions. The research confirmed the organizational chaos which negatively affects the way psycho -on- cologists practice their profession. As a consequence the legislator intervention is required in order to modify the legal regulation of this profession.
{"title":"Opinion of representatives of the psycho-oncology community on the lack of coherent systemic solutions on the legal regulation of their profession","authors":"K. Kocańda, Michał Chrobot, M. Samardakiewicz, M. Jabłoński","doi":"10.5603/ocp.2023.0031","DOIUrl":"https://doi.org/10.5603/ocp.2023.0031","url":null,"abstract":"Introduction. The profession of psycho-oncologist in Poland is not sufficiently regulated by law. Current solutions in the system involve contradictory regulations on obtaining qualifications to practice, which produces in effect systemic chaos and result in limited availability of services provided to oncology patients and their families by practitioners of this demanding profession. Material and methods. A survey conducted among psycho-oncologists concerning their professional identity was used in order to examine their opinion on the current legal regulations of this profession and the possible consequences of incoherent law solutions. The study used an original anonymous questionnaire entitled Survey on selected aspects of the psycho-oncology profession in the context of its scope and method of legal regulation and the Job Satisfaction Scale questionnaire. Results. The study showed that the inconsistency in legal regulations may result in restricted access to this profession, indicated doubts concerning the legal credentials required to use the professional title of psycho-oncologist and the lack of symmetry in individual competencies of practitioners with different underlying profession. Conclusions. The research confirmed the organizational chaos which negatively affects the way psycho -on- cologists practice their profession. As a consequence the legislator intervention is required in order to modify the legal regulation of this profession.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"36 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78275445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Renata Langford, Maciej Krzakowski, D. Kowalski, Rafał Krenke, T. Orłowski, Witold Rzyman, Bartosz Wasąg
{"title":"STANOWISKO EKSPERTÓW DOTYCZĄCE LECZENIA UZUPEŁNIAJĄCEGO OZYMERTYNIBEM CHORYCH NA NIEDROBNOKOMÓRKOWEGO RAKA PŁUCA PO RADYKALNEJ RESEKCJI NOWOTWORU","authors":"Renata Langford, Maciej Krzakowski, D. Kowalski, Rafał Krenke, T. Orłowski, Witold Rzyman, Bartosz Wasąg","doi":"10.5603/ocp.2023.0018","DOIUrl":"https://doi.org/10.5603/ocp.2023.0018","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"55 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76253460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Faris Tüzün, S. Ebinç, M. Kaplan, İ. Kaplan, H. Kömek, Z. Oruç, Şadiye Kemal Tuzcu, B. Taşdemir
Introduction. This study aimed to examine the efficacy of positron emission tomography in fusion with computed tomography (PET-CT) parameters in predicting survival outcomes for patients with malignant pleural mesothelioma. Material and methods. This study retrospectively evaluated the data of 250 patients who were followed up after a diagnosis of malignant pleural mesothelioma. The relationship of pre-treatment [maximum standardized uptake value (SUV max1 ), metabolic tumor volume (MTV1), total lesion glycolysis (TLG1), tumor/background (TBR1), pleural thickness1), post-treatment (SUV max2 , MTV2, TLG2, TBR2, pleural thickness2], and D PET-CT parameters with survival was retrospectively evaluated in 36 patients whose pre-and post-treatment CT scan examinations were complete. Results. The median age of the patients was 57.5 years, ranging from 35 to 76. Median follow-up time was 16 months, with a range of 7 to 42 months. Median survival was calculated as 18.8 months for all patients. Based on the determined cut-off values, overall survival was determined as 29.9 months in patients with TLG2 ≤ 158 compared to 16 months in patients with TLG2 > 158 (p = 0.009) and as 30.9 months in patients with D TLG ≤ –62.58 compared to 16 months in patients with D TLG > –62.58 (p = 0.001). In addition, median overall survival (OS) was determined as 29.9 months in patients with MTV2 ≤ 63.9 compared to 16 months in patients with MTV2 > 63.9 (p = 0.007) and as 29.9 months in patients with D MTV ≤ –54.03 compared to 16 months in patients with D MTV > –54.03 (p = 0.002). When evaluated with respect to TBR2; median OS was 29.9 months in patients with TBR2 ≤ 1.84 compared to 16 months in patients with TBR2 > 1.84 (p = 0.039). Conclusions. Our research findings indicate a correlation between OS and volumetric PET-CT measures, specifically TLG and MTV.
{"title":"Effects of the changes between preand post-treatment 18F-FDG PET-CT volumetric parameters on overall survival in pleural mesothelioma","authors":"Faris Tüzün, S. Ebinç, M. Kaplan, İ. Kaplan, H. Kömek, Z. Oruç, Şadiye Kemal Tuzcu, B. Taşdemir","doi":"10.5603/ocp.2023.0022","DOIUrl":"https://doi.org/10.5603/ocp.2023.0022","url":null,"abstract":"Introduction. This study aimed to examine the efficacy of positron emission tomography in fusion with computed tomography (PET-CT) parameters in predicting survival outcomes for patients with malignant pleural mesothelioma. Material and methods. This study retrospectively evaluated the data of 250 patients who were followed up after a diagnosis of malignant pleural mesothelioma. The relationship of pre-treatment [maximum standardized uptake value (SUV max1 ), metabolic tumor volume (MTV1), total lesion glycolysis (TLG1), tumor/background (TBR1), pleural thickness1), post-treatment (SUV max2 , MTV2, TLG2, TBR2, pleural thickness2], and D PET-CT parameters with survival was retrospectively evaluated in 36 patients whose pre-and post-treatment CT scan examinations were complete. Results. The median age of the patients was 57.5 years, ranging from 35 to 76. Median follow-up time was 16 months, with a range of 7 to 42 months. Median survival was calculated as 18.8 months for all patients. Based on the determined cut-off values, overall survival was determined as 29.9 months in patients with TLG2 ≤ 158 compared to 16 months in patients with TLG2 > 158 (p = 0.009) and as 30.9 months in patients with D TLG ≤ –62.58 compared to 16 months in patients with D TLG > –62.58 (p = 0.001). In addition, median overall survival (OS) was determined as 29.9 months in patients with MTV2 ≤ 63.9 compared to 16 months in patients with MTV2 > 63.9 (p = 0.007) and as 29.9 months in patients with D MTV ≤ –54.03 compared to 16 months in patients with D MTV > –54.03 (p = 0.002). When evaluated with respect to TBR2; median OS was 29.9 months in patients with TBR2 ≤ 1.84 compared to 16 months in patients with TBR2 > 1.84 (p = 0.039). Conclusions. Our research findings indicate a correlation between OS and volumetric PET-CT measures, specifically TLG and MTV.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"3 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79692553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Therapy with TRK inhibitors is a tumor-agnostic treatment directed against specific molecular changes rather than cancer type. NTRK fusions are rare in most prevalent cancers, accounting for less than 0.5% of cases. However, there is a group of rare cancers in which NTRK fusion is more prevalent. These include secretory carcinoma of the breast and salivary gland, childhood sarcomas, such as infantile fibrosarcoma, and cellular and mixed con - genital mesoblastic nephroblastoma. The most common rearrangement pertains to NTRK3 and the most common fusion gene is ETV6 . Identifying patients with NTRK gene fusions who would likely benefit from targeted therapy with TRK inhibitors requires practical diagnostic tools and an appropriate management strategy of diagnostic trajectory. The fusions can be detected by molecular biology techniques or pan-TRK immunohistochemistry. The latter detects NTRK1/2/3 gene fusions independently of the resulting fusion gene but does not determine which of them has been rearranged or what the fusion partner is. The sensitivity and specificity of the method reach 97% and 100%, respectively. Other advantages include the relatively low cost, short duration of examination, and broad accessibility of immunohistochemistry laboratories. These characteristics make this method a useful screening tool for detecting patients with NTRK gene fusions.
{"title":"Pan-TRK immunohistochemistry as a tool in the screening for NTRK gene fusions in cancer patients","authors":"M. Durzyńska, I. Michalek","doi":"10.5603/ocp.2023.0024","DOIUrl":"https://doi.org/10.5603/ocp.2023.0024","url":null,"abstract":"Therapy with TRK inhibitors is a tumor-agnostic treatment directed against specific molecular changes rather than cancer type. NTRK fusions are rare in most prevalent cancers, accounting for less than 0.5% of cases. However, there is a group of rare cancers in which NTRK fusion is more prevalent. These include secretory carcinoma of the breast and salivary gland, childhood sarcomas, such as infantile fibrosarcoma, and cellular and mixed con - genital mesoblastic nephroblastoma. The most common rearrangement pertains to NTRK3 and the most common fusion gene is ETV6 . Identifying patients with NTRK gene fusions who would likely benefit from targeted therapy with TRK inhibitors requires practical diagnostic tools and an appropriate management strategy of diagnostic trajectory. The fusions can be detected by molecular biology techniques or pan-TRK immunohistochemistry. The latter detects NTRK1/2/3 gene fusions independently of the resulting fusion gene but does not determine which of them has been rearranged or what the fusion partner is. The sensitivity and specificity of the method reach 97% and 100%, respectively. Other advantages include the relatively low cost, short duration of examination, and broad accessibility of immunohistochemistry laboratories. These characteristics make this method a useful screening tool for detecting patients with NTRK gene fusions.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"5 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91172772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Gruszczyńska, Krzysztof Kowalik, K. Hetman, A. Modrzejewski
Pancreatic cancer, despite significant medical advances, is still a significant clinical problem. This article focuses on discussing risk factors, diagnostic methods, and treatment options. These elements are crucial in making a prompt diagnosis and initiating treatment. On average, a physician in primary care sees a patient with undi - agnosed pancreatic cancer once every few years. Knowing the underlying symptoms and referring the patient to an appropriate center can significantly increase survival. Diagnostic methods include physical examination, numerous imaging techniques, and determination of tumor markers in serum. Surgical treatment combined with adjuvant chemotherapy is the only chance of cure for pancreatic cancer patients qualified for surgery. However, most patients experience tumor recurrence. When a tumor recurs, treatment for these patients and patients with unresectable disease is palliative chemotherapy. Numerous studies are currently underway to improve diagnostic and treatment methods.
{"title":"Pancreatic adenocarcinoma — current trends in diagnosis and treatment","authors":"A. Gruszczyńska, Krzysztof Kowalik, K. Hetman, A. Modrzejewski","doi":"10.5603/ocp.2023.0016","DOIUrl":"https://doi.org/10.5603/ocp.2023.0016","url":null,"abstract":"Pancreatic cancer, despite significant medical advances, is still a significant clinical problem. This article focuses on discussing risk factors, diagnostic methods, and treatment options. These elements are crucial in making a prompt diagnosis and initiating treatment. On average, a physician in primary care sees a patient with undi - agnosed pancreatic cancer once every few years. Knowing the underlying symptoms and referring the patient to an appropriate center can significantly increase survival. Diagnostic methods include physical examination, numerous imaging techniques, and determination of tumor markers in serum. Surgical treatment combined with adjuvant chemotherapy is the only chance of cure for pancreatic cancer patients qualified for surgery. However, most patients experience tumor recurrence. When a tumor recurs, treatment for these patients and patients with unresectable disease is palliative chemotherapy. Numerous studies are currently underway to improve diagnostic and treatment methods.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"48 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90714562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Filip Zieliński, R. Wojciechowski, Joanna Terebińska, Anna Skrzypczyk-Ostaszewicz, Szymon Tomaszewski, Artur Maliborski, K. Sklinda, Hanna Cyngot, W. Solarek, Magdalena Dobosz-Foligowska, R. Duchnowska
A 72-year-old man with a metastatic KRAS gene mutated colon adenocarcinoma was admitted to the hospital for effort dyspnea and subfebrile body temperature. He was after transversostomy in 2019 and in the course of a palliative chemotherapy FOLFIRI regimen (irinotecan, calcium folinate, 5-fluorouracil) with secondary prophylaxis with filgrastim. On admission (August 2020), his general condition was quite good — Eastern Cooperative Oncology Group Performance Scale 1 (ECOG PS 1). He reported fatigue, dyspnea, partial loss of taste, and cold sweat. A polymerase chain reaction test (RT-PCR; KIT LabSystem) was positive for SARS-CoV-2 (RdRP, E, and N gene positive). In this period, the variant of the concern (VC) was primarily Wuhan SARS-CoV-2. Non-contrast computed tomography (NCCT) of the chest showed ground glass opacifications in the subpleural region, focal consolidations, and moderate pleural effusion, mostly in the lower field of the right lung (Fig. 1A, B). The patient was admitted to a single-ward hospital for the treatment of pneumonia. He received oxygen therapy, a prophylactic dose of low molecular weight heparin, ceftriaxone, and 1 unit of convalescent plasma. He finished the treatment after 13 days, obtaining the elimination of the virus confirmed by the RT-PCR test and resolution of inflammatory changes in the control NCCT (Fig. 2A, B). Due to treatment with convalescent plasma, he was not qualified for direct vaccination against SARS-CoV-2. Then, from 09/2020, due to colon cancer progression, he received the second-line palliative chemotherapy FOLFOX4 (oxaliplatin, calcium folinate, 5-fluorouracil). In April 2021, he was hospitalized in the Surgery Department to restore the continuity of the digestive tract. After the operation, the SARS-CoV-2 RT-PCR test was positive again. In this period, the British variant (Alpha)
{"title":"SARS-CoV-2 recurrent infections in a patient with metastatic colon cancer during chemotherapy","authors":"Filip Zieliński, R. Wojciechowski, Joanna Terebińska, Anna Skrzypczyk-Ostaszewicz, Szymon Tomaszewski, Artur Maliborski, K. Sklinda, Hanna Cyngot, W. Solarek, Magdalena Dobosz-Foligowska, R. Duchnowska","doi":"10.5603/ocp.2023.0019","DOIUrl":"https://doi.org/10.5603/ocp.2023.0019","url":null,"abstract":"A 72-year-old man with a metastatic KRAS gene mutated colon adenocarcinoma was admitted to the hospital for effort dyspnea and subfebrile body temperature. He was after transversostomy in 2019 and in the course of a palliative chemotherapy FOLFIRI regimen (irinotecan, calcium folinate, 5-fluorouracil) with secondary prophylaxis with filgrastim. On admission (August 2020), his general condition was quite good — Eastern Cooperative Oncology Group Performance Scale 1 (ECOG PS 1). He reported fatigue, dyspnea, partial loss of taste, and cold sweat. A polymerase chain reaction test (RT-PCR; KIT LabSystem) was positive for SARS-CoV-2 (RdRP, E, and N gene positive). In this period, the variant of the concern (VC) was primarily Wuhan SARS-CoV-2. Non-contrast computed tomography (NCCT) of the chest showed ground glass opacifications in the subpleural region, focal consolidations, and moderate pleural effusion, mostly in the lower field of the right lung (Fig. 1A, B). The patient was admitted to a single-ward hospital for the treatment of pneumonia. He received oxygen therapy, a prophylactic dose of low molecular weight heparin, ceftriaxone, and 1 unit of convalescent plasma. He finished the treatment after 13 days, obtaining the elimination of the virus confirmed by the RT-PCR test and resolution of inflammatory changes in the control NCCT (Fig. 2A, B). Due to treatment with convalescent plasma, he was not qualified for direct vaccination against SARS-CoV-2. Then, from 09/2020, due to colon cancer progression, he received the second-line palliative chemotherapy FOLFOX4 (oxaliplatin, calcium folinate, 5-fluorouracil). In April 2021, he was hospitalized in the Surgery Department to restore the continuity of the digestive tract. After the operation, the SARS-CoV-2 RT-PCR test was positive again. In this period, the British variant (Alpha)","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"34 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78013384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Duc Thanh Le, Tu Anh Do, Lap Thanh Bui, Kien Hung Do, C. Nguyen
Introduction. Neoadjuvant chemotherapy for HER2-positive breast cancer consists of a chemotherapy regimen plus trastuzumab with or without pertuzumab. The use of trastuzumab has been shown to improve pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS). Purposes: To evaluate the efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab (TCH) in the treatment of HER2-positive breast cancer in Vietnamese patients. Material and methods. This retrospective study reviewed stage II–III HER2-positive breast cancer patients who received neoadjuvant docetaxel, carboplatin, and trastuzumab (TCH) at the Vietnamese National Cancer Hospital. The primary endpoint was the pCR rate which was defined as the absence of invasive tumor in the breast and axil - lary nodes (ypT0/is, ypN0). The secondary endpoints were DFS, OS, and toxicities. Results. The complete and partial clinical response of 51 patients were 33.3% and 58.8%, respectively. The pCR rate was 41.2%; there was a significantly higher response in cT1-2 patients compared to cT3-4 ones (61.1% vs. 39.3%, p = 0.033). Three-year estimated DFS and OS rates were 81.3% and 93.0%, respectively. Treatment was generally well tolerated. Grade 3/4 neutropenia and anemia were uncommon (21.6% and 7.8%). No symptomatic cardiac dysfunction occurred. Conclusions. Neoadjuvant TCH, non-anthracycline chemotherapy with single anti-HER2 regimen achieved high efficacy, with a good pCR rate and favorable tolerability in stage II or III HER2-positive breast cancer patients.
介绍。her2阳性乳腺癌的新辅助化疗包括化疗方案加曲妥珠单抗加或不加帕妥珠单抗。曲妥珠单抗已被证明可改善病理完全缓解(pCR)、无病生存期(DFS)和总生存期(OS)。目的:评价多西他赛、卡铂和曲妥珠单抗(TCH)治疗越南her2阳性乳腺癌患者的疗效和安全性。材料和方法。这项回顾性研究回顾了在越南国立肿瘤医院接受新辅助多西他赛、卡铂和曲妥珠单抗治疗的II-III期her2阳性乳腺癌患者。主要终点是pCR率，定义为乳腺和腋淋巴结无浸润性肿瘤(ypT0/is, ypN0)。次要终点为DFS、OS和毒性。结果。51例患者临床完全缓解率为33.3%，部分缓解率为58.8%。pCR率为41.2%;cT1-2患者的反应明显高于cT3-4患者(61.1% vs. 39.3%， p = 0.033)。3年估计DFS和OS率分别为81.3%和93.0%。治疗总体耐受良好。3/4级中性粒细胞减少症和贫血少见(21.6%和7.8%)。无症状性心功能障碍发生。结论。新辅助TCH、非蒽环类化疗单抗her2方案对II期或III期her2阳性乳腺癌患者疗效高，pCR率好，耐受性好。
{"title":"Pathological complete response and survival of HER2-positive invasive breast cancer following docetaxel, carboplatin, and trastuzumab neoadjuvant therapy: a Vietnamese experience","authors":"Duc Thanh Le, Tu Anh Do, Lap Thanh Bui, Kien Hung Do, C. Nguyen","doi":"10.5603/ocp.2023.0020","DOIUrl":"https://doi.org/10.5603/ocp.2023.0020","url":null,"abstract":"Introduction. Neoadjuvant chemotherapy for HER2-positive breast cancer consists of a chemotherapy regimen plus trastuzumab with or without pertuzumab. The use of trastuzumab has been shown to improve pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS). Purposes: To evaluate the efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab (TCH) in the treatment of HER2-positive breast cancer in Vietnamese patients. Material and methods. This retrospective study reviewed stage II–III HER2-positive breast cancer patients who received neoadjuvant docetaxel, carboplatin, and trastuzumab (TCH) at the Vietnamese National Cancer Hospital. The primary endpoint was the pCR rate which was defined as the absence of invasive tumor in the breast and axil - lary nodes (ypT0/is, ypN0). The secondary endpoints were DFS, OS, and toxicities. Results. The complete and partial clinical response of 51 patients were 33.3% and 58.8%, respectively. The pCR rate was 41.2%; there was a significantly higher response in cT1-2 patients compared to cT3-4 ones (61.1% vs. 39.3%, p = 0.033). Three-year estimated DFS and OS rates were 81.3% and 93.0%, respectively. Treatment was generally well tolerated. Grade 3/4 neutropenia and anemia were uncommon (21.6% and 7.8%). No symptomatic cardiac dysfunction occurred. Conclusions. Neoadjuvant TCH, non-anthracycline chemotherapy with single anti-HER2 regimen achieved high efficacy, with a good pCR rate and favorable tolerability in stage II or III HER2-positive breast cancer patients.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"20 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83497005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：